Published in Am J Surg Pathol on September 01, 2016
Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet (2009) 2.80
Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol (2000) 2.16
Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int (2002) 2.15
Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology (2000) 2.12
Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. Eur Heart J (2000) 2.01
Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest (2006) 1.91
Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation (2009) 1.84
Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. Am J Epidemiol (2006) 1.73
Quantitation, tissue distribution and proliferation kinetics of Kupffer cells in normal rat liver. Hepatology (1986) 1.71
Absorption and lipoprotein transport of sphingomyelin. J Lipid Res (2005) 1.38
The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal study. Pediatrics (2004) 1.25
Biochemical studies in Niemann-Pick disease. I. Major sphingolipids of liver and spleen. Biochim Biophys Acta (1983) 1.25
A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics (2008) 1.23
Lipid abnormalities in children with types A and B Niemann Pick disease. J Pediatr (2004) 1.22
Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab (Lond) (2006) 1.20
High-resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology. J Histochem Cytochem (2005) 1.16
Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis (2006) 1.12
Sphingomyelin inhibits the lecithin-cholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding. J Biol Chem (1996) 1.12
Erythrocyte sedimentation rate, coronary atherosclerosis, and cardiac mortality. Eur Heart J (2003) 1.05
Functional implications of liver cell heterogeneity. Gastroenterology (1981) 1.03
Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies. J Invest Dermatol (2004) 1.03
Morbidity and mortality in type B Niemann-Pick disease. Genet Med (2013) 1.00
The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med (2006) 0.99
Very low levels of high density lipoprotein cholesterol in four sibs of a family with non-neuropathic Niemann-Pick disease and sea-blue histiocytosis. J Med Genet (1990) 0.95
Liver and skin histopathology in adults with acid sphingomyelinase deficiency (Niemann-Pick disease type B). Am J Surg Pathol (2012) 0.93
Regulation of high-density lipoprotein metabolism. Circ Res (2014) 0.91
Increased sphingomyelin content impairs HDL biogenesis and maturation in human Niemann-Pick disease type B. J Lipid Res (2005) 0.91
Pulmonary involvement by Niemann-Pick disease. A report of six cases. Histopathology (2006) 0.90
C-reactive protein, fatal and nonfatal coronary artery disease, stroke, and peripheral artery disease in the prospective EPIC-Norfolk cohort study. Arterioscler Thromb Vasc Biol (2013) 0.89
HDL and atherosclerosis: Insights from inherited HDL disorders. Biochim Biophys Acta (2014) 0.89
Effects of sphingomyelin and cholesterol on lipoprotein lipase-mediated lipolysis in lipid emulsions. J Lipid Res (1998) 0.88
C-reactive protein promotes atherosclerosis by increasing LDL transcytosis across endothelial cells. Br J Pharmacol (2014) 0.88
ESI-MS quantitation of increased sphingomyelin in Niemann-Pick disease type B HDL. J Lipid Res (2005) 0.87
Approach to the patient with extremely low HDL-cholesterol. J Clin Endocrinol Metab (2012) 0.86
Regulation of plasma cholesterol esterification by sphingomyelin: effect of physiological variations of plasma sphingomyelin on lecithin-cholesterol acyltransferase activity. Biochim Biophys Acta (2012) 0.83
Acid sphingomyelinase (Asm) deficiency patients in The Netherlands and Belgium: disease spectrum and natural course in attenuated patients. Mol Genet Metab (2012) 0.83
Sphingolipids: major regulators of lipid metabolism. Curr Opin Clin Nutr Metab Care (2007) 0.83
Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency. Mol Genet Metab (2015) 0.83
Effects of sphingomyelin on apolipoprotein E- and lipoprotein lipase-mediated cell uptake of lipid particles. Biochim Biophys Acta (2003) 0.80
An in vitro hepatic zonation model with a continuous oxygen gradient in a microdevice. Biochem Biophys Res Commun (2014) 0.78
Acid sphingomyelinase deficiency: cardiac dysfunction and characteristic findings of the coronary arteries. J Inherit Metab Dis (2006) 0.78
Cirrhosis and liver failure: expanding phenotype of Acid sphingomyelinase-deficient niemann-pick disease in adulthood. JIMD Rep (2014) 0.77
Optimization of a histopathological biomarker for sphingomyelin accumulation in acid sphingomyelinase deficiency. J Histochem Cytochem (2012) 0.76
Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA (2006) 4.51
A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med (2006) 4.04
Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr (2004) 3.86
Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol (2006) 3.45
The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med (2003) 3.28
Identification of the gene (BBS1) most commonly involved in Bardet-Biedl syndrome, a complex human obesity syndrome. Nat Genet (2002) 2.94
Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol (2009) 2.88
Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet (2013) 2.82
Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics (2009) 2.44
A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood (2010) 2.38
A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab (2006) 2.27
Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology (2006) 2.08
Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med (2005) 2.06
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med (2012) 2.05
TIPS for refractory ascites: a 6-year single-center experience with expanded polytetrafluoroethylene-covered stent-grafts. AJR Am J Roentgenol (2015) 1.99
Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood (2007) 1.92
The role of human HtrA1 in arthritic disease. J Biol Chem (2005) 1.91
Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med (2011) 1.89
Molecular analysis expands the spectrum of phenotypes associated with GLI3 mutations. Hum Mutat (2010) 1.88
Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation (2007) 1.86
Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol (2009) 1.84
The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations. Am J Hum Genet (2002) 1.74
A quantifiable proliferative burst of tissue macrophages restores homeostatic macrophage populations after acute inflammation. Eur J Immunol (2011) 1.70
Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest (2003) 1.69
IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol (2008) 1.69
Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol (2003) 1.68
Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl (2008) 1.68
IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A (2005) 1.66
Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genet Med (2003) 1.62
Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transplant (2003) 1.60
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis (2014) 1.60
Distinct bone marrow-derived and tissue-resident macrophage lineages proliferate at key stages during inflammation. Nat Commun (2013) 1.58
Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis (2011) 1.54
Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFNgamma-dependent iNOS expression in the vasculature of healthy mice. Blood (2008) 1.53
Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency. Am J Hum Genet (2005) 1.51
Implications of the serine protease HtrA1 in amyloid precursor protein processing. Proc Natl Acad Sci U S A (2005) 1.47
De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45
A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol (2010) 1.44
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int (2013) 1.43
Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis. Eur J Gastroenterol Hepatol (2014) 1.40
12/15-Lipoxygenase regulates the inflammatory response to bacterial products in vivo. J Immunol (2008) 1.38
Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood (2007) 1.37
Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J Immunol (2010) 1.36
Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum (2006) 1.36
Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol (2009) 1.35
The pediatric cardiomyopathy registry and heart failure: key results from the first 15 years. Heart Fail Clin (2010) 1.34
Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol Genet Metab (2010) 1.30
Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem (2011) 1.29
Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J (2008) 1.29
Neurologic and neurodevelopmental phenotypes in young children with early-treated combined methylmalonic acidemia and homocystinuria, cobalamin C type. Mol Genet Metab (2013) 1.28
Evaluation of complex inheritance involving the most common Bardet-Biedl syndrome locus (BBS1). Am J Hum Genet (2003) 1.27
High prevalence of structural heart disease in children with cblC-type methylmalonic aciduria and homocystinuria. Mol Genet Metab (2009) 1.26
The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol (2013) 1.24
A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics (2008) 1.23
Lipid abnormalities in children with types A and B Niemann Pick disease. J Pediatr (2004) 1.22
Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. J Immunol (2009) 1.22
Interleukin-6 is crucial for recall of influenza-specific memory CD4 T cells. PLoS Pathog (2008) 1.21
Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry. Eur J Pediatr (2012) 1.20
Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease. J Biol Chem (2009) 1.18
Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol (2010) 1.17
Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J Immunol (2004) 1.14
A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl (2005) 1.13
Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte. Mol Genet Metab (2009) 1.11
Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB. PLoS One (2012) 1.08
Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I. J Inherit Metab Dis (2010) 1.08
Early and late outcome of cardiac surgery in patients with liver cirrhosis. Liver Transpl (2007) 1.08
Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum (2006) 1.07
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05
Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol (2007) 1.03
Cardiac phenotypes in chromosome 4q- syndrome with and without a deletion of the dHAND gene. Genet Med (2003) 1.03
Sleep enhances IL-6 trans-signaling in humans. FASEB J (2006) 1.03
Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection. Blood (2010) 1.02
Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J Inherit Metab Dis (2010) 1.02
A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Mol Genet Metab (2008) 1.01
Differential dependencies of monocytes and neutrophils on dectin-1, dectin-2 and complement for the recognition of fungal particles in inflammation. PLoS One (2012) 1.01
Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology (2012) 1.01
Arginase deficiency with lethal neonatal expression: evidence for the glutamine hypothesis of cerebral edema. J Pediatr (2003) 1.01
Macrophage heterogeneity and acute inflammation. Eur J Immunol (2011) 1.01
Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. FASEB J (2010) 1.01
Enhanced neutrophil migratory activity following major blunt trauma. Injury (2005) 1.01
Morbidity and mortality in type B Niemann-Pick disease. Genet Med (2013) 1.00
Type B Niemann-Pick disease: findings at chest radiography, thin-section CT, and pulmonary function testing. Radiology (2005) 1.00
Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice. Mol Ther (2012) 1.00
Clinical presentation of 13 patients with subtelomeric rearrangements and a review of the literature. Am J Med Genet A (2004) 1.00
Contiguous deletion of the X-linked adrenoleukodystrophy gene (ABCD1) and DXS1357E: a novel neonatal phenotype similar to peroxisomal biogenesis disorders. Am J Hum Genet (2002) 1.00
Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey. Genet Med (2010) 0.99
Foxp3⁺ Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production. Eur J Immunol (2012) 0.98
Interferon-gamma protects against the development of structural damage in experimental arthritis by regulating polymorphonuclear neutrophil influx into diseased joints. Arthritis Rheum (2007) 0.98
Identification and characterization of eight novel SMPD1 mutations causing types A and B Niemann-Pick disease. Mol Med (2010) 0.98
Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study. Am J Med Genet A (2014) 0.98
Competing risks for death and cardiac transplantation in children with dilated cardiomyopathy: results from the pediatric cardiomyopathy registry. Circulation (2011) 0.98
The response of interleukin-6 and soluble interleukin-6 receptor isoforms following intermittent high intensity and continuous moderate intensity cycling. Cell Stress Chaperones (2010) 0.97
Secretion of oncostatin M by infiltrating neutrophils: regulation of IL-6 and chemokine expression in human mesothelial cells. J Immunol (2002) 0.97
Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. Eur J Immunol (2013) 0.96
Ocular manifestations of Niemann-Pick disease type B. Ophthalmology (2004) 0.96
Sp1 and Sp3 mediate constitutive transcription of the human hyaluronan synthase 2 gene. J Biol Chem (2006) 0.96